Patent US4786590A successfully refreshed from Google Patents.
US4786590A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Diagnostic and therapeutic aspects of receptor-mediated leukemogenesis
Assignee: BOARD O TRUSTEES O LELAND STANFORD JR UNIVERSITY A CORP OF CA
•
Filing: 1985-01-15
•
Granted: 1988-11-22
•
Expires: 2005-01-15
Abstract
Abstract Specific binding members are provided for binding to lymphocytic cell surface receptors, which receptors are involved in the activation of a cell from the G 0 state into the cell division cycle to proliferate. The cell surface receptors are further characterized by binding to envelope proteins of neoplasia-causing retroviruses, and/or to intact retroviral particles.
Inventors
- 👤 Michael S. McGrath
- 👤 Irving L. Weissman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-10 00:52
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/5005; G01N33/5091; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6835; A61K47/6849; C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K2317/00; C07K2317/70; C07K2317/73; Y; Y10; Y10S; Y10S436/00; Y10S436/811; Y10S436/813
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
103 words
A method for detecting the presence of tumor cells in a warm-blooded animal host, said method comprising: combining a physiological sample suspected of containing a cell surface membrane receptor (CSMR) with a compound capable of binding to said CSMR, where said CSMR is characterized by: (1) being involved in the activation of cells from the resting phase to the cell division cycle; and (2) capable of specifically binding to a binding site of a transforming retrovirus; and determining the level of complex formation between said compound and said CSMR as compared to a predetermined value, as indicative of the presence of tumor cells.
Claim 2
Independent Claim
103 words
A method for detecting the presence of tumor cells in a warm-blooded animal host, said method comprising: combining a physiological sample suspected of containing a cell surface membrane receptor (CSMR) with a compound capable of binding to said CSMR, where said CSMR is characterized by: (1) being involved in the activation of cells from the resting phase to the cell division cycle; and (2) capable of specifically binding to a binding site of a transforming retrovirus; and determining the level of complex formation between said compound and said CSMR as compared to a predetermined value, as indicative of the presence of tumor cells.
Claim 3
Dependent Claim
12 words
A method according to claim 1, wherein said cell is a lymphocyte.
Claim 4
Dependent Claim
21 words
A method according to claim 2, wherein said compound binds to the variable region of the recognition receptor for said lymphocyte.
Claim 5
Dependent Claim
17 words
A method according to claim 3, wherein said recognition receptor is an α, β-heterodimer of a T-cell.
Claim 6
Dependent Claim
13 words
A method according to claim 3, wherein said recognition receptor is an immunoglobulin.
Claim 7
Independent Claim
102 words
A method for detecting lymphoma or leukemia in a mammalian host, which comprises: combining a physiological sample from said host containing lymphocytic cell surface membrane receptors, wherein said receptors are characterized by: (1) being the recognition receptor for the lymphocyte; and (2) specifically binding to a slow transforming retrovirus antigen binding site, with a monoclonal antibody specific for the variable region of said recognition receptor, under conditions permitting complex formation between said receptor and said monoclonal antibody; and determining whether the level of complex formation is elevated as compared to a predetermined value, where said elevation is indicative of abnormal cellular proliferation.
Claim 8
Independent Claim
102 words
A method for detecting lymphoma or leukemia in a mammalian host, which comprises: combining a physiological sample from said host containing lymphocytic cell surface membrane receptors, wherein said receptors are characterized by: (1) being the recognition receptor for the lymphocyte; and (2) specifically binding to a slow transforming retrovirus antigen binding site, with a monoclonal antibody specific for the variable region of said recognition receptor, under conditions permitting complex formation between said receptor and said monoclonal antibody; and determining whether the level of complex formation is elevated as compared to a predetermined value, where said elevation is indicative of abnormal cellular proliferation.
Claim 9
Dependent Claim
14 words
A method according to claim 6, wherein said sample is blood or blood fraction.
Claim 10
Dependent Claim
16 words
A method according to claim 7, wherein said sample is lymph node or other lymphoid tissue.
Claim 11
Dependent Claim
12 words
A method according to claim 7, wherein said mammalian host is human.
Claim 12
Dependent Claim
25 words
A method according to claim 6, wherein said lymphoma or leukemia is a T-cell lymphoma or leukemia and said recognition receptor is the α, β-heterodimer.
Claim 13
Dependent Claim
23 words
A method according to claim 6, wherein said lymphoma or leukemia is B-cell lymphoma or leukemia and said recognition receptor is an immunoglobulin.
Claim 14
Independent Claim
91 words
A method for treating a host suspected of having a tumor caused by a transforming retrovirus, said method comprising: administering to said host a growth retarding amount of a compound which specifically binds to a cell surface membrane receptor of said tumor cell, wherein said receptor is characterized by: (1) being involved in the activation of a cell from the resting phase to the cell division cycle; and (2) specifically binding to an antigen of said retrovirus; whereby the proliferation of said cells having said cell surface membrane receptor is retarded.
Claim 15
Independent Claim
91 words
A method for treating a host suspected of having a tumor caused by a transforming retrovirus, said method comprising: administering to said host a growth retarding amount of a compound which specifically binds to a cell surface membrane receptor of said tumor cell, wherein said receptor is characterized by: (1) being involved in the activation of a cell from the resting phase to the cell division cycle; and (2) specifically binding to an antigen of said retrovirus; whereby the proliferation of said cells having said cell surface membrane receptor is retarded.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-11-22 | 1992-05-23 | 1992-11-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-11-22 | 1996-05-23 | 1996-11-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-11-22 | 2000-05-23 | 2000-11-22 | $7700.00 | Window Closed / Lapsed |